title: TNF alpha antagonist therapy and safety monitoring.
abstract: OBJECTIVE
  To develop and/or update fact sheets about TNFα antagonists treatments, in order to assist physicians in the management of patients with inflammatory joint disease.
  
  
  METHODS
  1. selection by a committee of rheumatology experts of the main topics of interest for which fact sheets were desirable; 2. identification and review of publications relevant to each topic; 3. development and/or update of fact sheets based on three levels of evidence: evidence-based medicine, official recommendations, and expert opinion. The experts were rheumatologists and invited specialists in other fields, and they had extensive experience with the management of chronic inflammatory diseases, such as rheumatoid. They were members of the CRI (Club Rhumatismes et Inflammation), a section of the Société Francaise de Rhumatologie. Each fact sheet was revised by several experts and the overall process was coordinated by three experts.
  
  
  RESULTS
  Several topics of major interest were selected: contraindications of TNFα antagonists treatments, the management of adverse effects and concomitant diseases that may develop during these therapies, and the management of everyday situations such as pregnancy, surgery, and immunizations. After a review of the literature and discussions among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points: 1. in RA and SpA, initiation and monitoring of TNFα antagonists treatments, management of patients with specific past histories, and specific clinical situations such as pregnancy; 2. diseases other than RA, such as juvenile idiopathic arthritis; 3. models of letters for informing the rheumatologist and general practitioner; 4. and patient information.
  
  
  CONCLUSIONS
  These TNFα antagonists treatments fact sheets built on evidence-based medicine and expert opinion will serve as a practical tool for assisting physicians who manage patients on these therapies. They will be available continuously at www.cri-net.com and updated at appropriate intervals.
authors.affiliation: Rheumatology Department, CHU Sainte-Marguerite, Marseille, France. thao.pham@mail.ap-hm.fr
authors.forename: Thao
authors.initials: T
authors.lastname: Pham
authors.forename: Hervé
authors.initials: H
authors.lastname: Bachelez
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Berthelot
authors.forename: Jacques
authors.initials: J
authors.lastname: Blacher
authors.forename: Yoram
authors.initials: Y
authors.lastname: Bouhnik
authors.forename: Pascal
authors.initials: P
authors.lastname: Claudepierre
authors.forename: Arnaud
authors.initials: A
authors.lastname: Constantin
authors.forename: Bruno
authors.initials: B
authors.lastname: Fautrel
authors.forename: Philippe
authors.initials: P
authors.lastname: Gaudin
authors.forename: Vincent
authors.initials: V
authors.lastname: Goëb
authors.forename: Laure
authors.initials: L
authors.lastname: Gossec
authors.forename: Philippe
authors.initials: P
authors.lastname: Goupille
authors.forename: Séverine
authors.initials: S
authors.lastname: Guillaume-Czitrom
authors.forename: Eric
authors.initials: E
authors.lastname: Hachulla
authors.forename: Isabelle
authors.initials: I
authors.lastname: Huet
authors.forename: Denis
authors.initials: D
authors.lastname: Jullien
authors.forename: Odile
authors.initials: O
authors.lastname: Launay
authors.forename: Marc
authors.initials: M
authors.lastname: Lemann
authors.forename: Jean-Francis
authors.initials: JF
authors.lastname: Maillefert
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Marolleau
authors.forename: Valérie
authors.initials: V
authors.lastname: Martinez
authors.forename: Charles
authors.initials: C
authors.lastname: Masson
authors.forename: Jacques
authors.initials: J
authors.lastname: Morel
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
authors.forename: Stanislas
authors.initials: S
authors.lastname: Pol
authors.forename: Xavier
authors.initials: X
authors.lastname: Puéchal
authors.forename: Pascal
authors.initials: P
authors.lastname: Richette
authors.forename: Alain
authors.initials: A
authors.lastname: Saraux
authors.forename: Thierry
authors.initials: T
authors.lastname: Schaeverbeke
authors.forename: Martin
authors.initials: M
authors.lastname: Soubrier
authors.forename: Anne
authors.initials: A
authors.lastname: Sudre
authors.forename: Tu-Anh
authors.initials: TA
authors.lastname: Tran
authors.forename: Manuelle
authors.initials: M
authors.lastname: Viguier
authors.forename: Olivier
authors.initials: O
authors.lastname: Vittecoq
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.forename: Xavier
authors.initials: X
authors.lastname: Mariette
authors.forename: Jean
authors.initials: J
authors.lastname: Sibilia
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept